Auriga gets rights to new ADHD treatment
Auriga Laboratories, a US specialty pharmaceutical company, has signed a license agreement with Outlook Pharmaceuticals, under the terms of which it will have the exclusive rights to market and sell a new product indicated for the treatment of attention-deficit hyperactivity disorder in the USA. The new product combines one of the most frequently-prescribed drug classes for this condition, in a unique dosage form previously not available. The actual compound is not disclosed.
ADHD treatments are one of the most frequently prescribed product classes in the USA, with over 35 million prescriptions written by physicians, generating estimated sales of over $3.5 billion in America annually.
The product is expected to be approved by the Food and Drug Administration in early 2008 and launch during the second quarter of 2008. "This agreement solidifies Auriga's commitment to enhance our product portfolio with products approved using the ANDA and 505(b)(2) NDA regulatory pathways," said Philip Pesin, chief executive of Auriga.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze